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Background. Cannabis use is decreasing in England and Wales, while demand for cannabis treatment in addiction ser-
vices continues to rise. This could be partly due to an increased availability of high-potency cannabis.
Method. Adults residing in the UK were questioned about their drug use, including three types of cannabis (high
potency: skunk; low potency: other grass, resin). Cannabis types were proﬁled and examined for possible associations
between frequency of use and (i) cannabis dependence, (ii) cannabis-related concerns.
Results. Frequent use of high-potency cannabis predicted a greater severity of dependence [days of skunk use per
month: b = 0.254, 95% conﬁdence interval (CI) 0.161–0.357, p < 0.001] and this effect became stronger as age decreased
(b =−0.006, 95% CI −0.010 to −0.002, p = 0.004). By contrast, use of low-potency cannabis was not associated with de-
pendence (days of other grass use per month: b = 0.020, 95% CI −0.029 to 0.070, p = 0.436; days of resin use per
month: b = 0.025, 95% CI −0.019 to 0.067, p = 0.245). Frequency of cannabis use (all types) did not predict severity of can-
nabis-related concerns. High-potency cannabis was clearly distinct from low-potency varieties by its marked effects on
memory and paranoia. It also produced the best high, was preferred, and most available.
Conclusions. High-potency cannabis use is associated with an increased severity of dependence, especially in young
people. Its proﬁle is strongly deﬁned by negative effects (memory, paranoia), but also positive characteristics (best
high, preferred type), which may be important when considering clinical or public health interventions focusing on can-
nabis potency.
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Introduction
There is huge variation in the types of cannabis (mari-
juana) available worldwide (UNODC, 2014). This is
evident in illicit markets and also legal ones. For ex-
ample, an unprecedented number of cannabis products
and preparations are now available in Colorado
(Coombes, 2014). By contrast, sales in Uruguay may
be restricted to ﬁve strains only, with an upper limit
on potency (Coombes, 2014).
Cannabis potency is typically judged according to
concentrations of delta-9-tetrahydrocannabinol (THC),
the primary psychoactive constituent in cannabis.
However, the cannabis plant contains many other can-
nabinoids, most notably cannabidiol (CBD). These
other cannabinoids (and possibly other plant chemicals
known as terpenoids; Russo, 2011) contribute to po-
tency by moderating the effects of THC. For example,
CBD can block or dampen the effects of THC across
a range of domains (Zuardi et al. 1982; Morgan &
Curran, 2008; Morgan et al. 2010a,b, 2012; Englund
et al. 2012; Hindocha et al. 2015). These ﬁndings concur
with users’ ratings of cannabis potency, which are
positively correlated with THC and negatively with
CBD (Freeman et al. 2014).
Natural cannabinoid synthesis (and therefore canna-
bis potency) is inﬂuenced by a range of factors includ-
ing genetics, growing conditions (especially light),
harvest time, the part of the plant used, drying, storing
and processing (Potter, 2014). Mostproducts canbeclas-
siﬁed into three broad types: (1) high potency – indoor-
grown ﬂoral material of unfertilized plants, whereby
energy is diverted from seed production to cannabinoid
synthesis (‘skunk’, ‘sinsemilla’;meaning ‘without seeds’);
(2) low potency – outdoor-grown imported ﬂoral mater-
ial (‘herbal’, ‘grass’, ‘weed’); and (3) compressed blocks of
plantmatter (‘resin’, ‘hashish’). Skunk is characterized by
the highest THC content (∼15%), followed by imported
herbal/grass (∼9%) and then resin (∼5%), although
there is considerable variation within these categories
(Hardwick & King, 2008). Concentrations of CBD are
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typically low or completely absent in skunk and other
herbal/grass preparations. By contrast, resin/hashish
(and presumably landrace populations of cannabis
plants) typically contain comparable quantities of
THC and CBD (Potter et al. 2008). Thus, indoor-grown
ﬂoral cannabis (skunk) is the clearly most potent type
of cannabis (followed by imported herbal/grass, and
then resin/hashish), and might be expected to be
most strongly associated with any adverse effects of
cannabis use. This is currently an under-researched
area, although preliminary evidence suggests that
regular use of high-potency (skunk) cannabis is pre-
dictive of ﬁrst-episode psychosis (Di Forti et al. 2009)
and an earlier onset of psychosis, particularly among
daily users (Di Forti et al. 2013). By contrast, resin/hash-
ish is not linked to an increased risk of psychosis, even
among daily users (Di Forti et al. 2015).
It is estimated that 3.8%of theworld’s populationused
cannabis in the last year (UNODC, 2014) and this ﬁgure
has remained relatively stable in the last decade. In
England and Wales, however, prevalence of last year
use dropped from 10.7% to 6.6% between 2002/2003
and 2013/2014 (Home Ofﬁce, 2014). Despite this overall
reduction in use, demand for cannabis in addiction-
treatment services has continued to rise across the
same time period: between 2005/2006 and 2013/2014
new admissions for cannabis rose from 7579 to 11 821
in adults (NDTMS, 2014) and from 9043 to 13 659
among under 18s (NDTMS, 2015). There are now more
ﬁrst-time clients for cannabis treatment in Europe than
any other illicit drug (EMCDDA, 2014).
One possible explanation for these trends is an in-
crease in cannabis potency. Data from cannabis sei-
zures have documented rising THC concentrations in
the UK. This is predominantly due to an increase in
the availability of high-potency, indoor-grown (skunk)
cannabis which made up 15% of police seizures in
1999–2002 (King et al. 2004), 55% in 2004–2005 (Potter
et al. 2008) and 81% in 2007–2008 (Hardwick & King,
2008). These trends are matched by seizure data across
Europe (EMCDDA, 2014). Cannabis users titrate (use
less) as THC rises but only partially (Freeman et al.
2014; van der Pol et al. 2014) and not in response to
CBD (Freeman et al. 2014). It is therefore possible that
repeated exposure to high THC concentrations, and
little if any CBD, may have increased users’ depend-
ence on cannabis.
In this study, we recorded detailed information on
use of and experiences with different types of cannabis
through an online drug survey. This approach made it
possible to recruit a large sample who had used all of
three different cannabis types (skunk, other grass,
resin) within the last 12 months, permitting within-
subject comparison of cannabis types. We aimed to
test the hypothesis that severity of dependence, and
concerns about cannabis use, are more strongly asso-
ciated with use of high-potency than low-potency can-
nabis. Additionally, we explored users’ experiences of
each type of cannabis in relation to effects on memory,
paranoia, quality of high, preference, value for money
and availability.
Method
Design and participants
An online cross-sectional drugs survey, The Global
Drug Survey, was conducted in November 2009 as
reported elsewhere (Winstock et al. 2011). All partici-
pants conﬁrmed that they were aged 518 years, and
consented for the information they gave to be ana-
lysed. Ethical approval was received from the joint
South London and Maudsley and Institute of
Psychiatry National Health Service (NHS) Research
Ethics Committee.
Assessments
The survey collected demographic data and detailed
information on use of and experience with a number
of substances. The data presented and analysed in
this report is the UK data only; cases living in
England, Scotland, Wales, and Northern Ireland form
the UK dataset. Rather than recording information on
cannabis use generally (e.g. age when cannabis was
ﬁrst used, days of cannabis use per month), separate
questions were provided for (1) resin, (2) skunk grass
(hereafter ‘skunk’), (3) grass other (hereafter ‘other
grass’). This enabled each type to be rated as a separate
drug. The following information was collected for each
type of cannabis:
Comparing use of cannabis types
Used in the last 12 months? (yes/no).
Days used in the last month.
How long does ⅛th last you (in days).†
How many joints from ⅛th?
Proﬁling cannabis types
Respondents who had used all three cannabis types in
the last 12 months were asked to choose one type for
each of the following questions:
Which gives the best high?
Which is the best value for money?
Which is most likely to get you paranoid?
† One-eighth of an ounce (3.5 g), an amount typically sold in the
UK.
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Which is most likely to affect your memory?
Which is your preferred type?
Which is most available?
Route of administration
Respondents were asked whether they had ever used
cannabis using the following methods: smoked in
joint without tobacco, smoked in joint with tobacco,
smoked in bong/water pipe without tobacco, smoked
in bong/water pipe with tobacco, eaten/cooked, used
in a vaporizer.
Severity of dependence and cannabis-related concerns
These questions were assessed with reference to canna-
bis use generally. Cannabis dependence was assessed
using the Severity of Dependence Scale (SDS; Gossop
et al. 1995), which was adapted for the survey with
abbreviated response options as shown below. Scores
can range from 0 to 15, and scores 53 on the original
scale indicate dependence on cannabis (Swift et al.
1998).
(1) Do you ever think your use of cannabis is out of con-
trol? [never (0); sometimes (1); often (2); always (3)].
(2) Does the prospect of missing a smoke make you
very anxious or worried? [never (0); sometimes
(1); often (2); always (3)].
(3) Do you worry about your use of cannabis? [never
(0); sometimes (1); often (2); always (3)].
(4) Do you wish you could stop? [never (0); sometimes
(1); often (2); always (3)].
(5) How difﬁcult would you ﬁnd it to stop or go with-
out? [not difﬁcult (0); quite difﬁcult (1); very difﬁ-
cult (2); impossible (3)].
Additionally, the following questions were asked
(yes/no):
Have you ever discussed your cannabis use with a
healthcare professional?
Have you ever thought you might need treatment for
your cannabis use?
Have you ever sought treatment for cannabis use?
Have you ever tried to stop smoking cannabis?
Participants were also asked about a range of concerns
relating to their cannabis use:
We are interested in what worries you about smoking canna-
bis. Please rate the following possible health-related conse-
quences of smoking cannabis on a scale of 1–10, where 1 =
no concern for you and 10 = big concern for you: cancer,
chronic lung disease, effect on memory, effect on mental
health, legal issues, effect on relationships, effect on work or
study, lack of motivation.
Statistical analysis
Repeated-measures ANOVAmodels were used to com-
pare each cannabis type for indices of use.Post-hoc t tests
were corrected locally using the Bonferroni method. χ2
tests were used for comparing the proﬁle of cannabis
types. Current age was split into quartiles (<21, 21–22,
23–27 and >27 years) for analysis of ﬁrst use, and
proﬁle of effects. Pearson correlational analyses were
used to establish associations between cannabis use
variables and SDS scores. Multiple regression was
used to predict severity of cannabis dependence and
cannabis-related concerns from indices of cannabis
use. Analysis of gender was coded as female = 1,
male = 2, and age was entered as a continuous variable.
For all regression models, bias-corrected accelerated
95% conﬁdence intervals (CIs) were estimated using
10 000 boostrapping samples.
Results
Demographics
Data were available for 2514 respondents. In the last
year, prevalence of use was 72.5% for skunk, 68.6%
for other grass, and 58.7% for resin cannabis prepara-
tions. Thirty-seven per cent (929 respondents) had
used all three cannabis preparations in the last year;
all further analyses were conducted in this sample.
These participants had a mean age of 24.25 (S.D.=6.86)
years and 70.2% were male. Routes of administration
(ever used/most common use) were as follows: smoked
in joint with tobacco (98.9%/85.2%), smoked in joint
without tobacco (75.5%/5.5%), smoked in bong/water
pipe with tobacco (69.6%/3.3%), smoked in bong/
water pipe without tobacco (85.2%/4.5%), eaten/
cooked (80.1%/1.1%), used in a vaporizer (36.8%/0.4%).
Comparing use of cannabis types (Table 1)
Participants reported differences in the number of days
they had used each type of cannabis in the last month
(F2,761 = 38.332, p < 0.001, ŋp2 = 0.087). Skunk was used
for more days than other grass (p < 0.001) and resin
(p < 0.001), while other grass was used for more days
than resin (p < 0.001). No differences were found
for the number of days to smoke ⅛th (F2,895 = 1.655,
p = 0.197, ŋp2 = 0.003). Differences emerged for the num-
ber of joints made out of ⅛th (F2,893 = 62.710, p < 0.001,
ŋp2 = 0.108), reﬂecting a larger number of joints made
from resin compared to skunk (p < 0.001) or other
grass (p < 0.001); a similar number of joints were made
for skunk and other grass (p = 0.078). There were also
differences in age of ﬁrst use (F2,1432 = 41.059, p < 0.001,
ŋp2 = 0.043); resin was used earlier than skunk (p < 0.001)
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and other grass (p = 0.002); while other grass was used
earlier than skunk (p < 0.001).
The later age of skunk onset might be attributable to
its low availability at the time when this sample ﬁrst
tried cannabis (e.g. 15% prevalence in 1999–2002;
King et al. 2004). We explored this possibility by adding
abetween-subject factorof currentage, split into quartiles,
into themodel (see Fig. 1). This revealeda cannabis type ×
age interaction (F5,1468 = 29.456, p < 0.001, ŋp2 = 0.089) as
well as effects of cannabis type (F2,1468 = 53.598, p < 0.001,
ŋp2 = 0.056) and age (F3,900 = 42.331, p < 0.001, ŋp2 = 0.124).
Post-hoc tests showed that in young people (under 21’s
and 21- to 22-year-olds), all three types of cannabis were
ﬁrst tried at similar ages (all p’s > 0.06). By contrast, 23-
to 27-year-olds had tried resin earlier than other grass
(p < 0.001) and skunk (p = 0.010), which were both
tried at an equivalent age (p = 1.000). In the over 27’s,
there was a marked delay in ﬁrst trying skunk relative
to other grass (2.00 years, p < 0.001) and resin (2.42
years, p < 0.001), and resin was again tried earliest
(p = 0.002 compared to other grass). These data are con-
sistent with a shift in the relative availability of resin
and skunk over time, alongside a tendency for younger
people to try cannabis at an earlier age.
Proﬁling cannabis types (Fig. 2)
Ratings differed across the three cannabis types for
‘best high’ (χ22 = 539.919, p < 0.001), ‘value for money’
(χ22 = 126.788, p < 0.001), ‘most likely to get you para-
noid’ (χ22 = 719.880, p < 0.001), ‘most likely to affect
your memory’ (χ22 = 838.049, p < 0.001), ‘preferred type’
(χ22 = 246.739, p < 0.001), and ‘most available’ (χ
2
2 =
360.622, p < 0.001). As shown in Fig. 1, skunk scored
the highest for ‘best high’, ‘most likely to get you para-
noid’, ‘most likely to affect your memory’, ‘preferred
type’, ‘most available’. Among these, resin scored
above other grass for ‘best high’ (χ21 = 7.879, p = 0.005),
‘most likely to get you paranoid’ (χ21 = 18.447, p <
0.001) and ‘most likely to affect your memory’ (χ21 =
44.445, p < 0.001). By contrast, resin scored lower than
other grass for ‘most available’ (χ21 = 30.201, p < 0.001)
and they both scored equally for ‘preferred type’
(χ21 = 1.011, p = 0.315). In terms of ‘value for money’,
resin was rated the highest, above skunk (χ21 = 15.334,
p < 0.001), which in turn scored higher than other
grass (χ21 = 58.911, p < 0.001). The same pattern of results
was found when the sample was split according to
gender or age quartiles.
Severity of dependence and cannabis-related concerns
Exploratory correlations were conducted between SDS
scores and all 12 indices of use (for skunk, other grass
and resin: age of ﬁrst use, days used in the last month,
days taken to smoke ⅛th, number of joints from ⅛th).
For days used in the last month, Pearson’s r values
reﬂected a medium-large effect size for skunk (r = 0.432)
and small-medium effect sizes for other grass (r = 0.290)
and resin (r = 0.247). For all other indices of use, effect
sizeswere small (all r’s40.155). Scores for severity of de-
pendence (and individual concerns about cannabis)were
therefore regressed onto days of skunk, other grass, and
resin use in the last month.
Four hundred and three respondents hadused each of
the three cannabis types at least once in the last month;
the following analyses were conducted in those indivi-
duals. Within their lifetime, 23.0% had discussed their
cannabis use with a healthcare professional, 17.8%
thought they might need treatment for their cannabis
use, 5.3% had sought treatment for cannabis use, and
47.4% had tried to stop smoking cannabis. On the SDS,
they had amean score of 2.82 (S.D. = 3.29). Scores ranged
from 0 to 14 (out of amaximumof 15) and quartileswere
0.00, 2.00, and 4.50. When classiﬁed using the cut-off of
53 (Swift et al. 1998), 38% of the sample currently met
criteria for cannabis dependence.
As shown in Table 2, frequency of cannabis use in
the last month predicted severity of dependence,
accounting for 14.4% of the variance in these scores.
This was driven by skunk; no associations emerged
for other grass or resin. We additionally investigated
whether this effect was moderated by gender or age.
Adding gender and age into the model (step 2) did
not account for additional variance, but including
them as moderators of skunk use (step 3) improved
model ﬁt. Removing redundant predictors (step 4)
did not result in a loss of variance explained and
accounted for a total of 15.5%. SDS scores increased
(b = 0.254, 95% CI 0.161–0.357, p < 0.001) for each add-
itional day of skunk per month. This relationship be-
came stronger as age decreased (b =−0.006, 95% CI
−0.010 to −0.002, p = 0.004). SDS scores also increased
with age (b = 0.081, 95% CI 0.014–0.170, p = 0.039).
Table 1. Comparing use of three cannanbis types
Skunk Other grass Resin
Days used in the last
montha
14.05 (10.68) 11.46 (10.43) 9.45 (9.90)
Days taken to
smoke 3.5 g
8.55 (29.28) 7.31 (24.49) 8.14 (19.80)
Number of joints
made out of 3.5 ga
7.93 (5.12) 7.63 (4.87) 9.41 (5.70)
Age ﬁrst useda 15.90 (3.70) 15.38 (2.55) 15.18 (2.67)
Values given are mean (S.D.) scores.
a Difference across cannabis types at p < 0.001.
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Mean (S.D.) scores for cannabis-related concerns
about cannabis were as follows (presented in descend-
ing order of concerns). Memory: 4.98 (2.87); work or
study: 4.58 (2.98); mental health: 4.42 (3.16); motivation:
3.97 (3.50); chronic lung disease: 3.85 (2.76); cancer: 3.70
(2.75); relationships: 3.33 (2.71); legal issues: 3.01 (2.66).
Frequency of cannabis use (skunk, other grass, resin)
did not predict scores for any of these concerns.
Fig. 1. Current age and ﬁrst use of cannabis. Young people in the sample (currently under 23) were exposed to all three types
of cannabis at similar ages. Older people were exposed to resin earlier than other types of cannabis, and skunk use was
markedly delayed in the over 27’s. These results support a shift in the relative availability of resin and skunk over time.
Fig. 2. Characteristics of three cannabis types. Skunk was the predominant choice for all attributes apart from value for money.
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Discussion
This study compared the proﬁle of three cannabis types
and their associations with cannabis dependence. Our
ﬁndings clearly show that use of high-potency (skunk)
but not low-potency (other grass, resin) cannabis is asso-
ciated with an increased severity of dependence, espe-
cially in young people. Furthermore, the proﬁle of
high-potency (skunk) cannabis was marked in terms
of negative effects (memory and paranoia) but also
positive characteristics (preferred type and best high).
It was also rated as the most available type, but was
not the best value for money.
The past decade has seen a huge increase in the
prevalence of high-potency (skunk-type) cannabis in
England and Wales (King et al. 2004; Hardwick &
King, 2008; Potter et al. 2008; Freeman et al. 2014)
alongside rising demand for cannabis treatment in ad-
diction services (NDTMS, 2014, 2015). Our ﬁndings are
consistent with these observations, and are the ﬁrst to
our knowledge reporting a link between cannabis po-
tency and severity of drug dependence. Thus, clinically,
it might be useful (and desirable) to encourage skunk
users at risk of/experiencing dependence to move to
less potent forms of cannabis if they are not motivated
to quit.
Younger people were especially vulnerable, display-
ing a stronger relationship between extent of skunk use
and severity of dependence. This is in agreement with
observations that more under 18’s seek treatment for
cannabis than all adults combined, unlike any other
drug (NDTMS, 2014, 2015). Young people in our sam-
ple were also exposed to skunk from an earlier age;
older adults tried resin ﬁrst and had not tried skunk
until an average of 2.42 years later. Given that these
changes in the illicit market may have increased rates
of cannabis dependence in the UK, it will be important
to evaluate the impact of careful regulation of cannabis
potency (e.g. as planned in Uruguay) and other legisla-
tive changes (e.g. in the US) on cannabis dependence.
One explanation for our ﬁndings is that greater THC
exposure enhances the dependence-forming properties
of cannabis. This interpretation is in keeping with pre-
clinical research showing that THC is reinforcing in a
dose-dependent manner (Tanda et al. 2000; Justinova
et al. 2003). Titration by cannabis users appears to
counteract higher THC concentrations, but only par-
tially (Freeman et al. 2014; van der Pol et al. 2014). As
a result, episodic use of high-potency cannabis will
typically deliver larger doses of THC.
Interestingly, people in this study added less canna-
bis to their joints (based on the number of joints made
out of 3.5 g) when using resin compared to other types.
This may have further reduced their dose of THC, in
addition to the low potency typical of resin. However,
they took a similar number of days to smoke 3.5 g in
total – perhaps suggesting that resin users smoke
more joints with smaller amounts of cannabis (and pos-
sibly more tobacco), resulting in similar consumption of
raw cannabis overall. The presence of CBD may also be
relevant. Cannabis with a high ratio of CBD:THC (i.e.
resin) reduced attentional bias to drug cues (a process
implicated in addiction; Field & Cox, 2008) relative to
low CBD:THC cannabis (i.e. skunk) (Morgan et al.
2010b). CBD was also found to reduce symptoms of
Table 2. Predicting severity of cannabis dependence from frequency
of use
95% CI
b Lower Upper p
Step 1
Total R2 = 0.144, p < 0.001
Constant 1.046 0.636 1.473
Skunk 0.093 0.048 0.139 <0.001
Other grass 0.020 −0.029 0.070 0.436
Resin 0.025 −0.019 0.067 0.245
Step 2
ΔR2 = 0.003, p = 0.553
Total R2 = 0.147, p < 0.001
Constant 1.746 0.413 2.981
Skunk 0.096 0.051 0.143 <0.001
Other grass 0.018 −0.030 0.069 0.477
Resin 0.025 −0.018 0.067 0.245
Age −0.003 −0.046 0.050 0.905
Gender −0.380 −1.064 0.317 0.268
Step 3
ΔR2 = 0.023, p = 0.005
Total R2 = 0.170, p < 0.001
Constant 0.913 −0.874 2.537
Skunk 0.146 0.018 0.278 0.024
Other grass 0.014 −0.034 0.062 0.584
Resin 0.022 −0.021 0.064 0.298
Age 0.078 0.012 0.156 0.037
Gender −1.030 −2.142 0.094 0.058
Age × skunk −0.006 −0.010 −0.002 0.003
Gender × skunk 0.052 −0.019 0.121 0.160
Step 4
ΔR2 =−0.015, p = 0.138
Total R2 = 0.155, p < 0.001
Constant −0.733 −2.865 0.922
Skunk 0.254 0.161 0.357 <0.001
Age 0.081 0.014 0.170 0.039
Age × skunk −0.006 −0.010 −0.002 0.004
CI, Conﬁdence interval.
Signiﬁcant predictor variables are shown in bold.
Days of skunk use, but not other grass or resin, predicted
higher Severity of Dependence Scale scores. The relationship
between skunk use and severity of dependence became
stronger as age decreased.
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cannabis withdrawal in an open-label case study
(Crippa et al. 2012).
Although our results support a relationship between
cannabis potency and severity of dependence, they do
not imply a causal relationship, and many other factors
are likely to be involved. For example, a prospective
study found no independent associations between indi-
ces of cannabis use (including preferred type and THC
concentrations) and subsequent incidence of dependence
(van der Pol et al. 2013). This studydiffered fromours in
a number of respects, and included a number of add-
itional predictors (e.g. socio-demographic, vulnerability
and stress factors). Additionally, it used a between-
subjects comparison of preferred cannabis type and po-
tency as opposed to our within-subject analysis.
Contrary to our expectations, degree of cannabis use
did not predict level of concerns about cannabis (memory,
mental health, work or study, relationships, motivation,
chronic lung disease, cancer, legal issues). This might
reﬂect the varying susceptibility to cannabis-related
harmsbetween individuals.Another possible explanation
is that more frequent users hold the belief that their use is
not problematic. These ﬁndings also suggest that all
levels of use can be associated with modest health con-
cerns. This may imply that infrequent users who are not
currently using treatment services are nevertheless wor-
ried about the effects of cannabis, and might beneﬁt
from help at an individual or population-based level.
It is also noteworthy that memory emerged as the
strongest concern about cannabis use in this study, as
this was also the most deﬁning feature of high-potency
cannabis. This is consistent with the high THC, low
CBD proﬁle of skunk. When acutely administered,
THC produces robust and dose-dependent impairments
in verbal memory (Curran et al. 2002; D’Souza et al.
2004) and these impairments can be ameliorated by
co-administration of CBD (Morgan et al. 2010a; Englund
et al. 2012). Similarly, skunk was identiﬁed as the type of
cannabis most strongly associated with paranoia. This is
consistent with evidence that the paranoia-inducing
effects of THC can also be inhibited by CBD (Englund
et al. 2012), and that regular skunk use is associated with
an increased risk (Di Forti et al. 2009) and earlier onset
(Di Forti et al. 2013) of psychosis, while resin/hashish is
not, even in daily users (Di Forti et al. 2015).
Although skunk was most clearly deﬁned by these
negative effects, it was also rated as having the ‘best
high’ and was considered the ‘preferred type’. Clinical
and public health interventions related to high-potency
cannabis, focusing in its negative effects, should be
interpreted in the context of users’ own preferences.
Given that skunk was rated as the most available
type of cannabis, consistent with previous ﬁndings
(Hardwick & King, 2008; Potter et al. 2008; Freeman
et al. 2014) people who do prefer it will probably ﬁnd
it easy to obtain in the illicit market. On the other
hand, those who do not prefer skunk – or ﬁnd that
its negative effects outweigh the desirable ones –
may have little choice due to the current lack of avail-
able alternatives. Perhaps varieties of cannabis with
weaker effects on memory and paranoia (e.g. other
grass, resin) may be more desirable in this respect.
When comparing these lower potency varieties, it is
somewhat surprising that resin was rated as having a
better high and stronger effects on memory and para-
noia, given that it generally contains lower THC and
higher CBD than imported herbal cannabis (Hardwick
& King, 2008). It may be relevant that variation in
cannabinoid content is comparatively greater in resin
(Potter et al. 2008) and some resin can be highly potent
(e.g. 39.3% THC in the Netherlands; Pijlman et al.
2005). Such preparations are incredibly rare in the
UK (Potter et al. 2008) but perhaps experience with es-
pecially potent forms of resin could have led some peo-
ple to rate it as having the best high, and strongest
effects on memory and paranoia.
This study has some limitations. First, it used a self-
selecting (drug using) sample. This enabled a large
number of cannabis users to be recruited, but it does
limit the extent to which the ﬁndings can be attributed
to the general population, or more problematic users, as
dependence scores were modest on average. Second, be-
cause dependence was estimated using the SDS rather
than a structured clinical interview, it was not possible
to tease apart speciﬁc aspects of cannabis use disorder
such as tolerance, withdrawal, craving, failing obliga-
tions, giving up other recreational interests, and persist-
ent use in spite of problems. Additionally, the study
was cross-sectional and causality cannot be established
on the basis of these results. Indeed, it is quite plausible
that reverse causation might explain our ﬁndings (e.g.
as a result of dependence, people use more skunk).
Third, skunk was used for more days per month
than the other types, which might explain the reported
association with dependence. However, variance in
days per month of use was similar for each of the
three types, suggesting that these data were equally
appropriate to detect the existence of possible associa-
tions with dependence. Fourth, although we quantiﬁed
use of three different cannabis preparations, we cannot
be sure that the terms we used (e.g. skunk) were mean-
ingful to the population tested (Potter & Chatwin,
2012), although similarly named types were predictive
of actual THC and CBD concentrations elsewhere
(Freeman et al. 2014).
Conclusion
Use of high-potency (skunk) cannabis is associated
with an increased severity of dependence, especially
High potency cannabis and severity of dependence 3187
in young people. Skunk is also rated as having stronger
effects on memory impairment and paranoia than
other types of cannabis, but at the same time it pro-
duces the best high and is users’ preferred type.
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